

- 21 Sebagh M, Azoulay D, Roche B, Hoti E, Karam V, Teicher E, *et al.* Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation. *Liver Transpl* 2011; 17: 798–808.
- 22 Khettry U, Huang WY, Simpson MA *et al.* Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. *Hum Pathol* 2007; 38: 443–52.
- 23 Antonini TM, Sebagh M, Roque-Afonso AM *et al.* Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. *Am J Transplant* 2011; 11: 1686–95.
- 24 Honda M, Sakai A, Yamashita T *et al.* Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. *Gastroenterology* 2010; 139: 499–509.
- 25 Lyra AC, Fan X, Lang DM *et al.* Evolution of hepatitis C viral quasispecies after liver transplantation. *Gastroenterology* 2002; 123: 1485–93.
- 26 Arenas JL, Gallegos-Orozco JF, Laskus T *et al.* Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. *J Infect Dis* 2004; 189: 2037–46.
- 27 Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfecting with human immunodeficiency virus. *J Hepatol* 1997; 26: 975–82.
- 28 Lo CM, Cheung ST, Ng IO, Liu CL, Lai CL, Fan ST. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. *Liver Transpl* 2004; 10: 557–63.
- 29 Eghtesad B, Fung JJ, Demetris AJ *et al.* Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. *Liver Transpl* 2005; 11: 1343–52.

Sweden, and the Juvenile Diabetes Research Foundation. O.K. is in part supported by the National Institutes of Health (grant 2U01AI065192-06).

The authors declare no conflicts of interest.

Address correspondence to: Andrew S. Friberg, Ph.D., Division of Clinical Immunology, Department of Immunology, Genetics and Pathology, Uppsala University, Rudbeck Laboratory, C11, Dag Hammarskjölds väg 20, SE-75185 Uppsala, Sweden.

E-mail: andrew.friberg@igp.uu.se

A.S.F., O.K., and M.H. participated in the research design, performed the experiments and data analysis, and wrote the article.

Received 19 October 2012. Revision requested 12 November 2012.

Accepted 17 December 2012.

Copyright © 2013 by Lippincott Williams & Wilkins

ISSN: 0041-1337/13/9506-e36

DOI: 10.1097/TP.0b013e318283a859

REFERENCES

1. Antonioli B, Fermo I, Cainarca S, et al. Characterization of collagenase blend enzymes for human islet transplantation. *Transplantation* 2007; 84: 1568.
2. Barnett MJ, Zhai X, LeGatt DF, et al. Quantitative assessment of collagenase blends for human islet isolation. *Transplantation* 2005; 80: 723.
3. Balamurugan AN, Breite AG, Anazawa T, et al. Successful human islet isolation and transplantation indicating the importance of class I collagenase and collagen degradation activity assay. *Transplantation* 2010; 89: 954.
4. Brandhorst H, Asif S, Andersson K, et al. The effect of truncated collagenase class I isomers on human islet isolation outcome. *Transplantation* 2010; 90: 334.
5. Brandhorst H, Brendel MD, Eckhard M, et al. Influence of neutral protease activity on human islet isolation outcome. *Transplant Proc* 2005; 37: 241.
6. Kin T, O'Gorman D, Senior P, et al. Experience of islet isolation without neutral protease supplementation. *Islets* 2010; 2: 278.
7. Kin T, Zhai X, O'Gorman D, et al. Detrimental effect of excessive collagenase class II on human islet isolation outcome. *Transpl Int* 2008; 21: 1059.
8. Kin T, Zhai X, Murdoch TB, et al. Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. *Am J Transplant* 2007; 7: 1233.
9. Wolters GH, Vos-Scheperkeuter GH, van Deijnen JH, et al. An analysis of the role of collagenase and protease in the enzymatic dissociation of the rat pancreas for islet isolation. *Diabetologia* 1992; 35: 735.
10. Brandhorst H, Friberg A, Andersson HH, et al. The importance of tryptic-like activity in purified enzyme blends for efficient islet isolation. *Transplantation* 2009; 87: 370.
11. Balamurugan AN, Loganathan G, Bellin MD, et al. A new enzyme mixture to increase the yield and transplant rate of autologous and allogeneic human islet products. *Transplantation* 2012; 93: 693.
12. Cross SE, Hughes SJ, Partridge CJ, et al. Collagenase penetrates human pancreatic islets following standard intraductal administration. *Transplantation* 2008; 86: 907.
13. Balamurugan AN, He J, Guo F, et al. Harmful delayed effects of exogenous isolation enzymes on isolated human islets: relevance to clinical transplantation. *Am J Transplant* 2005; 5: 2671.
14. Van Wart HE, Steinbrink DR. A continuous spectrophotometric assay for *Clostridium histolyticum* collagenase. *Anal Biochem* 1981; 113: 356.
15. Goto M, Eich TM, Felldin M, et al. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. *Transplantation* 2004; 78: 1367.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; 72: 248.
17. Stoscheck CM. Quantitation of protein. *Methods Enzymol* 1990; 182: 50.

Impact of Conversion From Pegylated Interferon- α 2b to Interferon- α 2a for Treating Recurrent Hepatitis C After Liver Transplantation

The clinical outcomes of conversion from pegylated (peg) interferon (IFN)- α 2b to peg-IFN- α 2a therapy in combination with ribavirin for recurrent hepatitis C after liver transplantation (LT) have not been reported (1–3).

Living-donor liver transplantation (LDLT) was performed in 156 patients for hepatitis C at Kyushu University. Of these, 103 received peg-IFN- α 2b and ribavirin and 22 patients underwent conversion from peg-IFN- α 2b to peg-IFN- α 2a. Indications for conversion included (a) no response (NR; n=14) to peg-IFN- α 2b, (b) relapse after viral response (VR; n=5) following completing peg-IFN- α 2b therapy, and (c) to prevent relapse (n=3) for VR during peg-IFN- α 2b and ribavirin therapy. Splenectomy was performed in 47 (95.9%) recipients to prevent pancytopenia associated with antiviral therapy (4). The immunosuppression was induced with triple therapy of tacrolimus or cyclosporine with mycophenolate mofetil and steroids (5).

Peg-IFN- α 2b with ribavirin (Pegintron with Rebetol; Merck & Co., Whitehouse Station, NJ) was used as the primary treatment for recurrent hepatitis C after LDLT. Peg-IFN- α 2b was started at the dose of 0.5–1.0 μ g/kg per week with 200–400 mg per day of ribavirin. The doses were escalated in a stepwise manner up to 1.5 μ g/kg per week and 800 mg per day. Peg-IFN- α 2a with ribavirin (Pegasys with Copegus; Chugai Pharmaceutical, Chuo-ku, Tokyo, Japan) was primarily used for patients with NR or relapse during treatment with peg-IFN- α 2b with ribavirin. Peg-IFN- α 2a was started at the dose of 90–120 μ g per week with 200–400 mg per day of ribavirin. The doses were escalated in a stepwise manner up to 180 μ g per week and 800 mg per day. The serum hepatitis C virus (HCV)-RNA level was determined by a real-time HCV assay (AccuGene HCV; Abbott Molecular, Des Plaines, IL) and IL28B genotyping was performed using TaqMan GTXpress

Master Mix (Life Technologies, Tokyo, Japan). Peg-IFN-induced immune-mediated graft dysfunction (peg-IGD) was defined as the Levitsky et al. (6) did. Values are expressed as mean \pm standard deviation. Variables were analyzed using χ^2 tests for categorical values or the Mann–Whitney test for continuous variables. Values of $P < 0.05$ were considered statistically significant.

The characteristics of the patients who underwent conversion from peg-IFN- α 2b to peg-IFN- α 2a antiviral treatment are described in Table 1. The outcomes of conversion from peg-IFN- α 2b to peg-IFN- α 2a antiviral treatment are summarized in Figure 1. Among the 14 patients with NR following peg-IFN- α 2b with ribavirin therapy, 6 patients achieved VR and 3 had sustained VR (SVR) after conversion. Among the five patients with viral relapse following peg-IFN- α 2b-based therapy, four patients achieved VR after conversion. Among the three patients with conversion during

TABLE 1. Patient characteristics

Variables	Values
Recipient age, yr	51.4±8.6 (54.5)
Recipient gender, male	15 (68.2)
Donor age, yr	35.7±11.3 (34.5)
Donor gender, male	16 (72.7)
Left lobe graft	13 (59.7)
GV/SLV (%)	41.4±6.4 (40.4)
Splenectomy	17 (77.3)
Tacrolimus	12 (54.5)
Mycophenolate mofetil	20 (54.5)
Steroid free	5 (22.7)
HCV-RNA titer at LDLT, log IU/mL	5.5±0.6 (5.7)
IFN before LDLT	9 (40.9)
HCV genotype 1b, 2a, and 2b	16 (72.7), 5 (22.7), and 1 (4.6)
Donor rs8099917 genotype, T/T	7 (31.8)
Recipient rs8099917 genotype, T/T	8 (36.4)
Time from LDLT to peg-IFN-a2b, mo	14.3±18.2 (8.1)
Peg-IFN-a2b dose, mg/kg/wk	1.1±0.3 (1.0)
Ribavirin dose peg-IFN-a2b, mg/kg/d	6.1±2.9 (6.2)
Duration of peg-IFN-a2b treatment, mo	12.1±14.2 (10.7)
HCV-RNA titer at conversion, log IU/mL	4.1±2.6 (4.9)
Peg-IFN-a2a dose, mg/kg/wk	2.1±0.8 (1.9)
Ribavirin dose with peg-IFN-a2a, mg/kg/d	3.5±4.3 (2.1)
Duration of peg-IFN-a2a treatment, mo	14.2±10.1 (9.8)
VR with peg-IFN-a2b	8 (36.4)

GV, graft volume; HCV, hepatitis C virus; IFN, interferon; LDLT, living-donor liver transplantation; peg, pegylated; SLV, standard liver volume; VR, viral response.

(1.8±1.9 vs. 5.3±2.0 log IU/mL; $P<0.01$) and history of VR during peg-IFN- α 2a with ribavirin treatment (66.7% vs. 14.3%; $P=0.03$) were significantly associated with SVR after conversion (Table 4).

The major structural difference between peg-IFN- α 2b and peg-IFN- α 2a is the conjugated polyethylene glycol (7–10). Peg-IFN- α 2b (12 kDa) has a single-branched polyethylene glycol, whereas peg-IFN- α 2a (40 kDa) has bulky multiple branched conjugates. Consequently, peg-IFN- α 2a has a smaller distribution volume (10 vs. 40 L), longer absorption half-life (50 vs. 4.6 hr), and longer elimination half-life (80 vs. 40 hr). Moreover, it was reported that the serum concentration of peg-IFN- α 2a was 20 mg/mL at 7 days after injection compared with almost zero for peg-IFN- α 2b (8).

As a posttransplantation primary antiviral agent for recurrent hepatitis C, peg-IFN- α 2a was used in very limited series, and peg-IFN- α 2b has become the most widely used and studied regimen for use after LT (11–13). Among them, Dinges et al. (14) only reported the actual rate of SVR (47%) following peg-IFN- α 2a with ribavirin for 19 patients after LT, whereas dose

VR by peg-IFN- α 2b-based therapy, two patients achieved SVR. However, all three patients with conversion during VR by peg-IFN- α 2b-based therapy had peg-IGD, including de novo autoimmune hepatitis (n=2) and chronic rejection (n=1), resulting in graft loss in two patients.

The viral status after peg-IFN conversion is summarized in Table 2. Among patients with NR, relapse after VR, HCV-RNA seropositivity, and VR following peg-IFN- α 2b, the rates of VR after converting to peg-IFN- α 2a were 42.8%, 100.0%, 57.9%, and 100.0%, respectively. The rates of SVR were 21.4%, 80.0%, 36.8%, and 40.9%, respectively.

Univariate analysis was performed to identify factors associated with VR after conversion from peg-IFN- α 2a to peg-IFN- α 2b. In this analysis, only history of VR during peg-IFN- α 2a with ribavirin treatment (57.1% vs. 0.0%; $P=0.02$) was significantly associated with VR after conversion (Table 3). By contrast, low HCV-RNA titer at conversion




FIGURE 1. Twenty-two patients who received peg-IFN- α 2b with ribavirin were converted to peg-IFN- α 2a with or without ribavirin. *AIH (n=1); **AIH (n=1); ***AIH (n=1) and CR (n=1). AIH, autoimmune hepatitis; CR, chronic rejection; IFN, interferon; NR, no response; peg, pegylated; SVR, sustained viral response; VR, viral response.

TABLE 2. Viral status after conversion from peg-IFN- α 2b to peg-IFN- α 2a antiviral therapy

Response to peg-IFN- α 2b	VR for peg-IFN- α 2a (%)	SVR for peg-IFN- α 2a (%)
NR	6/14 (42.8)	3/14 (21.4)
Relapse after VR	5/5 (100.0)	4/5 (80.0)
Positive HCV-RNA	11/19 (57.9)	7/19 (36.8)
VR	3/3 (100.0)	2/3 (67.7)
Total	14/22 (63.6)	9/22 (40.9)

HCV, hepatitis C virus; IFN, interferon; NR, no response; peg, pegylated; SVR, sustained viral response; VR, viral response.

modification was necessary in 26% of patients. Although their study was small and nonrandomized, the rate of SVR was superior to that achieved by peg-IFN- α 2b with ribavirin (~30%) (15).

Restarting peg-IFN- α 2a with ribavirin in nontransplantation settings after a poor response to previous IFN therapy has been reported in a few studies (16–18). Jensen et al. (16) conducted a randomized trial in which

treatment was restarted in 950 patients who did not respond to prior peg-IFN- α 2b with ribavirin therapy. In that study, the rate of SVR after 72 weeks of peg-IFN- α 2a with ribavirin treatment was 16%. Herrine et al. (17) randomized 124 patients with poor response to peg-IFN- α 2b with ribavirin therapy. In that study, 37% of patients had SVR after conversion to peg-IFN- α 2a with ribavirin. Therefore, we think that

the 21.4% of SVR rate after conversion from peg-IFN- α 2b to IFN- α 2a is fairly acceptable.

However, the main adverse outcome of conversion to peg-IFN- α 2a is peg-IGD, a concept recently proposed by Levitsky et al. (6). It was reported that IFN could lead to IGD, which may include acute rejection, chronic rejection, and autoimmune hepatitis as well as graft loss (15, 19, 20). They reported that

TABLE 3. Predictors for VR after conversion from peg-IFN- α 2b to peg-IFN- α 2a

Variables	VR		P
	No (n=6)	Yes (n=14)	
Recipient age, yr	58.8±5.1	51.4±8.6	0.85
Recipient gender, male	3 (50.0)	11 (78.6)	0.20
Donor age, yr	32.5±11.1	34.5±9.5	0.68
Donor gender, male	3 (50.0)	11 (78.6)	0.20
Left lobe graft	3 (50.0)	8 (57.1)	0.77
GV/SLV, %	41.7±4.7	41.1±7.6	0.84
Splenectomy	4 (66.7)	11 (78.6)	0.57
Tacrolimus	4 (66.7)	6 (42.6)	0.33
Mycophenolate mofetil	6 (100.0)	12 (85.7)	0.33
Steroid free	2 (33.3)	3 (21.4)	0.57
HCV-RNA titer at LDLT, log IU/mL	5.7±0.2	5.6±0.6	0.67
IFN before LDLT	2 (33.3)	6 (42.9)	0.69
HCV genotype 1b, 2a, and 2b	6 (100.0)	9 (64.3)	0.09
Donor rs8099917 genotype, T/T	3 (50.0)	11 (78.6)	0.20
Recipient rs8099917 genotype, T/T	3 (50.0)	9 (64.3)	0.55
Time from LDLT to peg-IFN-a2b, mo	12.1±18.5	16.0±19.6	0.67
Peg-IFN-a2b dose, mg/kg/wk	1.1±0.3	1.0±0.3	0.35
Ribavirin dose, with peg-IFN-a2b, mg/kg/d	6.6±3.8	5.6±2.8	0.77
Duration of peg-IFN-a2b treatment, mo	20.8±24.8	8.9±5.6	0.52
HCV-RNA titer at conversion, log IU/mL	4.7±2.8	3.5±2.6	0.34
Peg-IFN-a2a dose, mg/kg/wk	2.2±0.8	1.9±0.8	0.51
Ribavirin dose, with peg-IFN-a2a, mg/kg/d	3.3±5.4	2.8±3.3	0.81
Duration of peg-IFN-a2a treatment, mo	26.7±16.2	12.9±10.5	0.06
VR with peg-IFN-a2b	0 (0.0)	8 (57.1)	0.02

GV, graft volume; HCV, hepatitis C virus; IFN, interferon; LDLT, living-donor liver transplantation; peg, pegylated; SLV, standard liver volume; VR, viral response.

TABLE 4. Predictors for SVR after conversion from peg-IFN- α 2b to peg-IFN- α 2a

Variables	SVR		P
	No (n=7)	Yes (n=9)	
Recipient age, yr	55.9 \pm 6.1	51.7 \pm 9.1	0.21
Recipient gender, male	4 (57.1)	7 (77.8)	0.38
Donor age, yr	33.7 \pm 12.1	39.0 \pm 9.5	0.30
Donor gender, male	3 (42.8)	8 (88.9)	0.06
Left lobe graft	4 (57.1)	5 (55.6)	0.95
GV/SLV (%)	42.6 \pm 5.5	39.2 \pm 7.7	0.24
Splenectomy	5 (71.4)	6 (66.7)	0.84
Tacrolimus	5 (71.4)	4 (44.4)	0.28
Mycophenolate mofetil	7 (100.0)	6 (66.7)	0.69
Steroid free	3 (42.8)	2 (22.2)	0.38
HCV-RNA titer at LDLT, log IU/mL	5.6 \pm 0.5	5.4 \pm 0.7	0.57
IFN before LDLT	2 (28.5)	4 (44.4)	0.51
HCV genotype 1b, 2a, 2b	7 (100.0)	6 (66.7)	0.09
Donor rs8099917 genotype, T/T	4 (57.1)	8 (88.9)	0.14
Recipient rs8099917 genotype, T/T	4 (57.1)	6 (66.7)	0.69
Time from LDLT to peg-IFN-a2b, mo	10.3 \pm 12.5	21.6 \pm 24.8	0.17
Peg-IFN-a2b dose, mg/kg/wk	1.1 \pm 0.3	1.0 \pm 0.3	0.35
Ribavirin dose, with peg-IFN-a2b, mg/kg/d	6.0 \pm 3.7	5.7 \pm 3.1	0.84
Duration of peg-IFN-a2b treatment, mo	12.7 \pm 17.6	11.1 \pm 5.4	0.78
HCV-RNA titer at conversion, log IU/mL	5.3 \pm 2.0	1.8 \pm 1.9	<0.01
Peg-IFN-a2a dose, mg/kg/wk	2.0 \pm 0.8	1.5 \pm 0.5	0.13
Ribavirin dose, with peg-IFN-a2a, mg/kg/d	3.2 \pm 5.0	2.6 \pm 3.2	0.79
Duration of peg-IFN-a2a treatment, mo	26.7 \pm 16.2	16.3 \pm 12.1	0.23
VR with peg-IFN-a2b	1 (14.3)	6 (66.7)	0.03

GV, graft volume; HCV, hepatitis C virus; IFN, interferon; LDLT, living-donor liver transplantation; peg, pegylated; SLV, standard liver volume; SVR, sustained viral response; VR, viral response.

7.2% of patients treated with peg-IFN develop peg-IGD over 10 years, with a significantly higher mortality rate. Additionally, the use of peg-IFN- α 2a (odds ratio=4.7) was a significant risk factor for this event (6). In the current series, peg-IGD occurred in all three patients who converted from peg-IFN- α 2b to peg-IFN- α 2a, with graft loss in two patients.

In conclusion, conversion to peg-IFN- α 2a-based antiviral therapy for recurrent hepatitis C after LT is a safe option, with increased VR and SVR rate, only for patients with NR or relapse on previous peg-IFN- α 2b therapy.

Toru Ikegami¹
Ken Shirabe¹
Tomoharu Yoshizumi¹
Norihiko Furusyo²
Kazuhiro Kotoh³
Masaki Kato³
Shinji Shimoda⁴
Yuji Soejima¹

Takashi Motomura¹
Takasuke Fukuhara¹
Yoshihiko Maehara¹

¹ Department of Surgery and Science
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan

² Department of General Internal Medicine
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan

³ Department of Medicine
and Bioregulatory Science
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan

⁴ Department of Medicine
and Biosystemic Science
Graduate School of Medical Sciences
Kyushu University
Fukuoka, Japan

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan.

The authors declare no conflicts of interest.

Address correspondence to: Toru Ikegami, M.D., Department of Surgery and Science, Graduate

School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

E-mail: tikesurg@ysurg2.med.kyushu-u.ac.jp

T.I. participated in the study conception and design and drafting of the article. K.S. participated in the critical revision of the article. T.Y. participated in the statistical analysis. N.E., T.M., and T.F. participated in the DNA analysis. K.K. participated in the study conception and design. M.K. and S.S. participated in the collection of clinical data. Y.S. participated in the pathologic examination. Y.M. participated in the final approval of the article.

Received 14 November 2012. Revision requested 10 December 2012.

Accepted 17 December 2012.

Copyright © 2013 by Lippincott Williams & Wilkins

ISSN: 0041-1337/13/9506-e38

DOI: 10.1097/TP.0b013e318283a82e

REFERENCES

- Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than Peginterferon alpha-2b in chronic hepatitis C: systematic review of randomized trials. *Hepatology* 2010; 51: 1176.
- Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and

- preliminary efficacy data. Hepatitis C Intervention Therapy Group. *Clin Pharmacol Ther* 2000; 68: 556.
3. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than Peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. *Gastroenterology* 2010; 138: 116.
 4. Ikegami T, Toshima T, Takeishi K, et al. Bloodless splenectomy during liver transplantation for terminal liver diseases with portal hypertension. *J Am Coll Surg* 2009; 208: e1.
 5. Ikegami T, Taketomi A, Soejima Y, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. *Transplantation* 2009; 88: 303.
 6. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. *Gastroenterology* 2012; 142: 1132.
 7. Sporea I, Danila M, Sirli R, et al. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. *J Gastrointest Liver Dis* 2006; 15: 125.
 8. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. *J Antimicrob Chemother* 2004; 53: 15.
 9. Escudero A, Rodríguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. *J Gastroenterol Hepatol* 2008; 23: 861.
 10. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. *Hepatology* 2009; 49: 22.
 11. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. *Liver Transpl* 2006; 12: 1067.
 12. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. *Am J Transplant* 2006; 6: 2348.
 13. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. *Liver Transpl* 2007; 13: 1100.
 14. Dinges S, Morard I, Heim M, et al. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. *Transpl Infect Dis* 2009; 11: 33.
 15. Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. *Am J Transplant* 2006; 6: 1586.
 16. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. *Ann Intern Med* 2009; 150: 528.
 17. Herrine SK, Brown RS Jr, Bernstein DE, et al. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. *Dig Dis Sci* 2005; 50: 719.
 18. Boo I, Fischer AE, Johnson D, et al. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)interferon/ribavirin. *J Clin Virol* 2007; 39: 288.
 19. Selzner N, Guindi M, Renner EL, et al. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. *J Hepatol* 2011; 55: 207.
 20. Takeishi K, Shirabe K, Toshima T, et al. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case. *Surg Today* 2011; 41: 1016.

ERRATUM

Anonymity and Live-Donor Transplantation: An ELPAT View: Erratum

In the February 27, 2013 issue of *Transplantation* in the article by Mamode et al, "Anonymity and Live-Donor Transplantation: An ELPAT View" the author Frank Dor should have been listed as Frank J.M.F. Dor.

REFERENCE

Mamode N, Lennerling A, Citterio F, et al. Anonymity and live-donor transplantation: an ELPAT view. *Transplantation*. 2013; 95: 536.

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C

Norihiro Furusyo¹, Eiichi Ogawa¹, Makoto Nakamuta², Eiji Kajiwara³, Hideyuki Nomura⁴, Kazufumi Dohmen⁵, Kazuhiro Takahashi⁶, Takeaki Satoh⁷, Koichi Azuma⁸, Akira Kawano⁹, Yuichi Tanabe¹⁰, Kazuhiro Kotoh¹¹, Shinji Shimoda¹², Jun Hayashi^{1,*},
The Kyushu University Liver Disease Study (KULDS) Group

¹Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan; ²Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan; ³Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan; ⁴The Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu, Japan; ⁵Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan; ⁶Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan; ⁷Center for Liver Disease, National Hospital Organization Kokura Medical Center, Kitakyushu, Japan; ⁸Department of Medicine, Kyushu Central Hospital, Fukuoka, Japan; ⁹Department of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan; ¹⁰Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan; ¹¹Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; ¹²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Background & Aims: This study was performed to evaluate the efficacy of a triple therapy in older Japanese patients; telaprevir (TVR) was added to pegylated interferon α 2b and ribavirin.

Methods: This prospective study enrolled 120 genotype 1b patients with chronic hepatitis C who received 12 weeks of triple therapy followed by a 12-week dual therapy that included pegylated interferon α 2b and ribavirin. Patients were categorized according to age: group A, 64 patients aged >60 and group B, 56 patients aged \leq 60. Serum HCV RNA levels were monitored by COBAS TaqMan HCV test.

Results: The rates of undetectable HCV RNA at week 4 (rapid virological response, RVR) were 73.4% in group A and 73.2% in group B. No significant difference in sustained virological response (SVR) was found between groups A (76.6%) and B (83.9%) ($p = 0.314$). The SVR rates for patients with interleukin 28B (*IL28B*) (rs8099917) TT allele (89.4% and 91.9% for groups A and B) were significantly higher than for those with the *IL28B* TG/GG allele (41.2% and 68.4%, respectively) (both $p < 0.05$). Mul-

tivariate analysis extracted *IL28B* TT and RVR as independent factors associated with SVR. Adverse effects resulted in treatment discontinuation by 12.5% in each group. Hemoglobin decrease significantly differed between groups A and B: the decrease to ≥ 100 g/L, to 85 – <100 g/L, and to <85 g/L, was 9.4%, 40.6%, and 50% in group A patients, respectively, and 41.1%, 25%, and 33.9% in group B patients, respectively ($p = 0.0006$).

Conclusions: TVR-based triple therapy can be successfully used to treat older patients with genotype 1b chronic hepatitis C.

© 2013 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.

Introduction

Chronic hepatitis C virus (HCV) infection affects approximately 170 million people worldwide and often causes cirrhosis and hepatocellular carcinoma (HCC) [1,2]. The ultimate goal of treatment for chronic hepatitis C is achieving sustained virological response (SVR), defined as undetectable HCV RNA in serum 6 months after the termination of treatment. A 48-week combination of pegylated interferon α (PegIFN- α) plus ribavirin (RBV) is successful for only about 45% of chronic hepatitis C patients infected with HCV genotype 1. Patients for whom treatment is unsuccessful are termed difficult-to-treat [3–6].

In Japan, the majority of patients are infected with HCV genotype 1 and they are older than patients in the United States and Europe. Such older patients have poor virological response to antiviral treatment [7–9], especially postmenopausal women [6]. Several studies have shown low SVR rates for older patients who received dual therapy with PegIFN- α and RBV [7,9,10]. It has been hypothesized that older patients have a decreased blood count and reduced cardiovascular, pulmonary, and kidney func-

Keywords: Chronic hepatitis C; Older patients; Telaprevir; Pegylated interferon α ; Ribavirin.

Received 10 January 2013; received in revised form 12 March 2013; accepted 13 March 2013; available online 28 March 2013

* Corresponding author. Address: Department of General Internal Medicine, Kyushu University Hospital, Higashi-Ku, Fukuoka 812-8582, Japan. Tel.: +81 92 642 5908; fax: +81 92 642 5916.

E-mail address: hayashij@gim.med.kyushu-u.ac.jp (J. Hayashi).

Abbreviations: TVR, telaprevir; RVR, rapid virological response; SVR, sustained virological response; *IL28B*, interleukin 28B; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; PegIFN- α , pegylated interferon α ; RBV, ribavirin; NS3/4A, non-structural 3/4A; DAA, direct-acting antiviral agent; KULDS, The Kyushu University Liver Disease Study; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ GTP, γ -glutamyl-transpeptidase; eGFR, estimated glomerular filtration rate; PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism; ITPA, inosine triphosphate pyrophosphatase; cEVR, complete early virological response; EOT, end-of-treatment response.



Research Article

tion, and thus are less resistant to the influence induced by treatment. This also leads to more adverse events and poorer drug adherence. Treatment strategies tailored to the needs of these difficult-to-treat chronic hepatitis C patients are necessary.

In the United States, Canada, the European Union, and Japan, telaprevir (TVR), an HCV non-structural 3/4A (NS3/4A) protease inhibitor, has recently been approved for the treatment of chronic hepatitis C genotype 1 and represents a new class of small molecules that are direct-acting antiviral agents (DAA) for reflecting HCV replication [11–14]. TVR-based triple therapy, combined with PegIFN- α and RBV, has resulted in an improved SVR rate, when compared to PegIFN- α monotherapy and PegIFN- α plus RBV dual therapy [15–19].

Earlier studies of TVR-based regimens for chronic hepatitis C have not shown any correlation between age and virological outcome. Furthermore, there are no data regarding differences in factors predictive of SVR by older and younger patients. For this reason, we conducted a prospective, multicenter study to investigate the efficacy and safety of TVR-based triple therapy for older patients with chronic hepatitis C.

Patients and methods

Patients

Since 2004, the Kyushu University Liver Disease Study (KULDS) Group has conducted a prospective, multicenter study to investigate the efficacy and safety of antiviral treatment in chronic hepatitis C patients [14,9]. Our more recent research, performed between December 2011 and November 2012, included 406 Japanese patients with HCV genotype 1b aged ≥ 20 years, who received TVR-based triple therapy. The current study was restricted to the 120 patients (age range 25–73 years) for whom data is currently available for their 24-week post-therapy follow-up. The older group (group A) consists of 64 patients aged >60 years and the younger group (group B) of 56 patients aged ≤ 60 years.

According to previous treatment response, relapse was defined as undetectable HCV RNA during and at the end of previous treatment, with HCV RNA positivity representing later on. Non-response was defined as detectable HCV RNA for more than 24 weeks. The study included 27 patients (22.5%) who were treatment naive, 64 (53.3%) with prior relapse, 25 (20.8%) with prior non-response, and 4 (3.3%) with unknown response.

Exclusion criteria were: positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; clinical or biochemical evidence of hepatic decompensation (ascites, bleeding varices, or encephalopathy); other causes of liver disease; excessive active alcohol consumption (>40 g/day of ethanol) or drug abuse; suspected HCC or active cancer at entry; chronic renal failure or creatinine clearance of ≤ 50 ml/min; very poorly controlled heart diseases, pulmonary disorders, diabetes, or thyroid diseases; depression, or its history, history of suicide attempt; pregnancy in progress or planned during the study period of either partner; or treatment with antiviral or immunosuppressive agents prior to enrollment. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of our hospital. Informed consent was obtained from all patients before enrollment. The study was registered as a clinical trial on the University Hospital Medical Information Network (ID 000009711).

Clinical assessment

Clinical parameters included serum albumin, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ -glutamyl-transpeptidase (γ GTP), estimated glomerular filtration rate (eGFR), whole blood cell count, and HCV RNA. Blood samples were taken for all patients at baseline, days 3 and 7, every week thereafter to week 24, and at the end of follow-up. Liver biopsy at entry for 76 (63.3%) of the 120 patients was done by two or more experienced hepatologists. For each specimen, the stage of fibrosis (F0–4) and grade of activity (A0–3) were established according to Metavir score [20].

Determination of HCV markers

The baseline and follow-up tests for HCV viremia were done by real-time polymerase chain reaction (PCR) assay (COBAS TaqMan HCV test v2.0, Roche Diagnostics, Tokyo, Japan), with a detectability of ≥ 15 IU/ml and the linear dynamic range of 1.2–7.8 log IU/ml. HCV genotype and the core amino acid substitution at position 70 of the HCV genome were determined before treatment for all patients. HCV genotype was determined by sequence determination in the 5' non-structural region of the HCV genome followed by phylogenetic analysis [21]. Amino acid substitution at position 70 of the core region was analyzed by direct sequencing, as reported previously [22].

Interleukin 28B and inosine triphosphate pyrophosphatase

Human genomic DNA was extracted from peripheral blood. Genotyping by the single-nucleotide polymorphism (SNP) of the interleukin 28B (*IL28B*) (rs8099917) gene was done using the TaqMan Allelic Discrimination Demonstration Kit (7500 Real-Time PCR System; Applied Biosystems, Foster City, CA) [21]. Patients were genotyped as TT, TG, or GG at the polymorphic site. Similarly, genotyping by the SNP of the inosine triphosphate pyrophosphatase (*ITPA*) (rs1127354) gene was done using the TaqMan Allelic Discrimination Demonstration Kit. Patients were genotyped as CC, CA, or AA at the polymorphic site [23].

Therapeutic protocol

All patients received 12-week triple therapy that included TVR (2250 mg/day) (Telaviv; Mitsubishi Tanabe Pharma, Osaka, Japan), PegIFN- α -2b (60–150 μ g/week) (PEG-Intron; MSD, Tokyo, Japan) and RBV (600–1000 mg/day) (Rebetol; MSD) followed by a 12-week dual therapy that included PegIFN- α -2b and RBV. TVR 750 mg was administered orally three times a day at an 8-h interval after each meal. PegIFN- α -2b was injected subcutaneously once weekly at a dose of 1.5 μ g/kg. RBV was given orally at a daily dose of 600–1000 mg based on body weight (600 mg for patients weighing <60 kg, 800 mg for those weighing 60–80 kg, and 1000 mg for those weighing >80 kg). The above durations and dosages are those approved by the Japanese Ministry of Health, Labor, and Welfare.

Efficacy of treatment

Successful treatment was SVR, defined as undetectable serum HCV RNA at 24 weeks after the end of treatment. Early virological response during the first 12 weeks of treatment was categorized as follows: rapid virological response (RVR), undetectable HCV RNA at week 4; complete early virological response (cEVR), detectable HCV RNA at week 4 but undetectable at week 12. End-of-treatment response (EOT) was defined as undetectable HCV RNA at the end of treatment. Relapse was defined as an EOT response but non-SVR.

Therapeutic dosage assessments

The dosages of the drugs used in triple therapy mainly depended on the possibility of adverse effects: anemia, leukopenia, thrombocytopenia, malaise, and anorexia. They were accomplished by reviewing the medical records and by counting the remaining pills of each patient to determine the total dosage actually administered over the treatment period. The dosages of TVR during three different periods (within the first 4 weeks, from week 5 to week 12, and within the first 12 weeks) were calculated individually as the percentage of TVR 2250 mg/day. The dosages of PegIFN- α -2b and RBV were calculated individually as averages on the basis of body weight at baseline. The percentages of the assigned total cumulative PegIFN- α -2b and RBV dosages were calculated individually.

Safety assessments

Adverse events and hematological and chemical laboratory data were assessed up to the last visit for each patient. We mainly monitored for rash, serious skin reactions, and anemia. Also, newly occurred and deteriorated comorbidities were assessed during the study period according to the Charlson comorbidity index [24].

Statistical analysis

Statistical analyses were performed using the SAS system, version 9.1.3 (SAS Institute, Cary, NC). Continuous data of patients are expressed as median with interquartile range. Univariate analyses were performed using the Chi-square, Fisher's exact test, Mann-Whitney *U* test, Cochran-Armitage test, or Bonferroni's correction, as appropriate, with SVR as the outcome. To identify independent factors for predicting an SVR, variables that reached the $p < 0.1$ level in univariate tests were used as candidate factors for multiple logistic regression analysis. The model was reduced using AIC-based forward and/or backward stepwise selection with bootstrap validation. A p value less than 0.05 was regarded as statistically significant in all analyses.

Results*Patient characteristics*

The patient characteristics are summarized by age in Table 1. Analysis of the pretreatment factors found male percentage, white blood cell count, hemoglobin, platelet count, serum albumin, γ GTP, and eGFR of group A to be significantly lower than those of group B (all $p < 0.05$). No significant difference in liver histology, prior treatment response, or *IL28B* or *ITPA* genotype was found between groups A and B. Analysis of treatment factors found the percentage of patients who were able to tolerate the assigned total cumulative PegIFN- α -2b dosage $\geq 80\%$ and RBV dosage $\geq 80\%$ to be significantly lower in group A than in group B ($p = 0.023$). The percentage of patients who were able to tolerate assigned total cumulative RBV dosage $\geq 80\%$ showed a similar difference ($p = 0.014$), as would be expected by the lower hemoglobin level at baseline.

Virological outcome and response

Table 2 shows the virological responses by age. RVR, cEVR, EOT, and SVR did not significantly differ between groups A and B patients (73.4% vs. 73.2%, 18.8% vs. 19.6%, 87.5% vs. 89.3, and 76.6% vs. 83.9%, respectively). Relapse was more frequently seen in group A (12.5%) compared with group B (6.0%), but with no significant difference ($p = 0.253$). Patients with RVR had a significantly higher SVR rate (89.4%, 42 of 47 in group A; 97.6%, 40 of 41 in group B) than patients with cEVR (41.7%, 5 of 12 in group A; 54.5%, 6 of 11 in group B) ($p = 0.0002$ for group A and $p < 0.0001$ for group B).

Fig. 1 shows differences in serum HCV RNA level at treatment day 3 by age and virological response. The median serum HCV RNA level at day 3 was significantly lower for RVR patients (2.6 log IU/ml for group A patients and 2.4 log IU/ml for group B patients) than for non-RVR patients (3.3 log IU/ml and 3.2 log IU/ml, respectively) ($p < 0.0001$). A significant difference in the level at day 3 was also found between SVR (2.7 log IU/ml and 2.6 log IU/ml, respectively) and non-SVR (3.0 log IU/ml and 3.2 log IU/ml, respectively) patients. No significant differences in the level at day 3 were found between group A and B patients.

Demographic and clinical features of patients by age and SVR

Table 3 shows the differences of patient demographic and clinical features by age and SVR. The SVR rates of the patients with *IL28B* (rs8099917) TT (42 of 47, 89.4% and 34 of 37, 91.9% for group A and B patients) were significantly higher than for *IL28B* TG/GG (7 of 17, 41.2% and 13 of 19, 68.4%, respectively) ($p < 0.0001$ and

$p = 0.023$). The SVR rates of the treatment naïve patients and those who had prior relapse (41 of 47, 87.2% and 39 of 44, 88.6% for group A and B patients) were higher than those of the patients who had prior non-response (5 of 14, 35.7% and 8 of 11, 72.7%, respectively), significantly different in group A ($p < 0.0001$), but with no significant difference in group B ($p = 0.180$).

We assessed the relationship between SVR and liver fibrosis only in the 76 patients who received liver biopsy at entry (Table 3). In group A, the more fibrosis progressed the more the SVR rate decreased significantly (100%, 100%, 83.3%, 100%, and 50% for the patients with F0, F1, F2, F3, and F4, respectively, $p = 0.007$). A similar trend was observed in group B (100%, 94.1%, 80%, 57.1%, and 66.7%, respectively), but with no significant difference ($p = 0.067$).

Of the 120 patients, 12 (10.0%) had to discontinue TVR due to adverse effects ($n = 10$), dropout ($n = 1$), and no virological effect ($n = 1$) (5, 4, and 3 patients at weeks 4, 8, and 11, respectively). Discontinuation of PegIFN- α -2b, RBV, and TVR significantly influenced an achievement of SVR in both groups (all $p < 0.0001$) (Table 3). The ability to tolerate the assigned total cumulative PegIFN- α -2b dosage $\geq 80\%$ was significantly related to the achievement of SVR only in group A patients ($p = 0.0002$). Patients in group A with SVR had a higher rate of tolerance of the assigned total cumulative RBV dosage $\geq 80\%$ than patients without SVR, but with no significant difference ($p = 0.061$).

SVR and drug adherence by age

We investigated the association between SVR and the cumulative exposure to TVR, as a percentage of the target dosage, during three different periods: within the first 4 weeks, from week 5 to week 12, and within the first 12 weeks. Within the first 4 weeks, patients with $< 60\%$ of the target dosage to TVR had extremely low SVR rates (group A: 3 of 5, 60.0% and group B: 1 of 3, 33.3%), compared to those with $\geq 60\%$ of the dosage (group A: 46 of 59, 78.0% and group B: 46 of 53, 86.8%), but with no significant difference. Significant differences in SVR rates were found between patients taking $< 60\%$ and $\geq 60\%$ of the target dosage to TVR in all the studied patients (4 of 8, 50% vs. 92 of 112, 82.1%), respectively, $p = 0.028$. No significant differences in the SVR rates were found between patients taking $< 60\%$ and $\geq 60\%$ of the target dosage from week 5 to week 12 (35 of 43, 81.4% vs. 61 of 77, 79.2%, respectively) and within the first 12 weeks (24 of 31, 77.4% vs. 72 of 89, 80.9%, respectively) in all the studied patients. Classified by age, no significant differences in the rates were found among the three periods.

We investigated the association between SVR and cumulative exposures to PegIFN- α -2b and RBV for the whole 24-week treatment period, as a percentage of the target dosage of each drug. Lower exposure to PegIFN- α -2b (3 of 9, 33.3% with exposure $< 60\%$; 2 of 4, 50% with exposure 60 to $< 80\%$; and 44 of 51, 86.3% with exposure $\geq 80\%$, $p = 0.009$) and to RBV (12 of 20, 60% with exposure $< 60\%$; 22 of 28, 78.6% with exposure 60 to $< 80\%$; and 15 of 16, 93.8% with exposure $\geq 80\%$, $p = 0.046$) was significantly related to lower SVR rates for group A but not for group B patients.

Predictive factors correlated with an SVR

Multiple logistic regression analysis identified the only three factors that independently influenced an SVR for group A patients:

Research Article

Table 1. Patient characteristics by age.

Variables	Group A Patients aged >60 (n = 64)	Group B Patients aged ≤60 (n = 56)	p value*
Men, n (%)	19 (29.7)	35 (62.5)	0.0003
Age (yr)	66.0 [7.0]	53.0 [10.2]	<0.0001
Age range (yr)	61-73	25-60	
Body mass index (kg/m ²)	23.0 [3.5]	23.7 [3.8]	0.159
Baseline co-morbidities, n (%)	12 (18.8)**	7 (12.5)***	0.349
Baseline HCV RNA (log ₁₀ IU/ml)	6.4 [0.7]	6.6 [0.7]	0.137
HCV core amino acid substitution at position 70, wild/mutation, n	33/31	25/31	0.449
White blood cell count (×10 ⁶ /L)	4165 [1300]	4890 [2862]	0.002
Hemoglobin level (g/L)	133 [18]	144 [22]	<0.0001
Platelet count (×10 ⁹ /L)	144 [47]	159 [83]	0.003
Serum albumin (g/L)	39 [5.0]	41 [5.0]	0.001
Aspartate aminotransferase (IU/L)	52.5 [48.5]	51 [48.4]	0.283
Alanine aminotransferase (IU/L)	55 [56.7]	58.5 [65.7]	0.920
γ-glutamyl-transpeptidase (IU/L)	32 [31.5]	56 [70]	0.003
Estimated glomerular filtration rate (ml/min)	75.4 [19.6]	83.7 [20.7]	<0.0001
Liver histology			
Stage, F0-2/F3-4, n	21/21	24/10	0.069
Grade, A0-1/A2-3, n	14/28	13/21	0.657
Not determined, n	22	22	
Previous treatment response			
Treatment naïve, n (%)	12 (18.8)	15 (26.8)	0.622
Prior relapse, n (%)	35 (54.7)	29 (51.8)	
Prior non-response, n (%)	14 (21.9)	11 (19.6)	
Prior unknown response, n (%)	3 (4.7)	1 (1.8)	
<i>IL28B</i> SNP (rs8099917)			
TT, n (%)	47 (73.4)	37 (66.1)	0.379
TG/GG, n (%)	17 (26.6)	19 (33.9)	
<i>ITPA</i> SNP (rs1127354)			
CC, n (%)	51 (79.7)	41 (73.2)	0.402
CA/AA, n (%)	13 (20.3)	15 (26.8)	
Completed assigned total cumulative PegIFN-α-2b dosage ≥80% and RBV dosage ≥80%, n (%)	15 (23.4)	24 (42.9)	0.023
Completed assigned total cumulative PegIFN-α-2b dosage ≥80%, n (%)	51 (79.7)	46 (82.1)	0.733
Completed assigned total cumulative RBV dosage ≥80%, n (%)	16 (25.0)	26 (46.4)	0.014
Discontinuation of PegIFN-α-2b and RBV, n (%)	8 (12.5)	7 (12.5)	>0.999
Discontinuation of TVR, n (%)	7 (10.9)	5 (8.9)	0.714
Discontinuation of treatment, n (%)	8 (12.5)	7 (12.5)	>0.999

HCV, hepatitis C virus; *IL28B*, interleukin 28B; SNP, single-nucleotide polymorphism; *ITPA*, inosine triphosphate pyrophosphatase; PegIFN-α-2b, pegylated interferon α2b; RBV, ribavirin; TVR, telaprevir.

All patients were infected with HCV genotype 1b.

Continuous variables are expressed as median [interquartile range].

*p Value draws a comparison between SVR and non-SVR patients.

**Group A included 12 patients with baseline comorbidities (1 with cerebrovascular disease but no paralysis, 3 with peptic ulcer disease, and 8 with diabetes mellitus), according to the Charlson comorbidity index [24] (except for liver disease).

***Group B included 7 patients with baseline comorbidities (2 with peptic ulcer disease and 5 with diabetes mellitus), according to the Charlson comorbidity index [24] (except for liver disease).

patients treatment naïve and with prior treatment relapse (odds ratio (OR) 8.403 for those with prior non-response, $p = 0.047$), *IL28B* TT genotype (OR 14.93 for non-TT genotype, $p = 0.017$) and RVR (OR 7.498 for non-RVR, $p = 0.009$) (Table 4). Similarly, multiple logistic regression analysis identified the only two factors that independently influenced an SVR for group B patients: *IL28B* TT genotype and RVR. *IL28B* TT genotype and RVR were common factors for SVR in both groups.

Adverse events and comorbidities

Adverse events were observed in all patients, most of them mild to moderate. The following serious adverse events and others resulted in discontinuation of treatment. Of the studied patients, 15 (12.5%) had to discontinue treatment. In group A, the reasons for discontinuation ($n = 8$) were severe anemia ($n = 2$), malaise ($n = 2$), anorexia ($n = 2$), deterioration of diabetes mellitus

Table 2. Treatment response of patients aged >60 and ≤60 years.

	Rate, n (%)		p value ^a
	Group A Patients aged >60 (n = 64)	Group B Patients aged ≤60 (n = 56)	
SVR	49 (76.6)	47 (83.9)	0.314
RVR	47 ^b (73.4)	41 ^c (73.2)	0.977
cEVR (not RVR)	12 ^b (18.8)	11 ^c (19.6)	0.901
EOT	56 (87.5)	50 (89.3)	0.761
Relapse	7 (12.5) ^d	3 (6.0) ^d	0.253

A sustained virological response (SVR) is defined as undetectable serum HCV RNA at 24 weeks after the end of treatment. A rapid virological response (RVR) is defined as undetectable HCV RNA at week 4. A complete early virological response (cEVR) is defined as detectable HCV RNA at week 4 but undetectable HCV RNA at week 12. End-of-treatment response (EOT) is defined as undetectable HCV RNA at the end of treatment. Relapse is defined as an EOT response but non-SVR. All patients were infected with HCV genotype 1b.

^ap Value draws a comparison between group A and B patients.

^bGroup A patients with RVR had a significantly higher SVR rate (42 of 47, 89.4%) than the patients with cEVR (5 of 12, 41.7%) ($p = 0.0002$).

^cGroup B patients with RVR had a significantly higher SVR rate (40 of 41, 97.6%) than patients with cEVR (6 of 11, 54.5%) ($p < 0.0001$).

^dRelapse rate is calculated by dividing the number of patients with relapse by those with EOT.




Fig. 1. Differences in serum HCV RNA levels at treatment day 3 by age and virological response. Medians are shown as horizontal bars. Boxes cover the interquartile range and tails show the minimum and maximum data. A zero of HCV RNA level indicates negativity. RVR, rapid virological response; SVR, sustained virological response.

(n = 1), and dropout (n = 1). In group B, the reasons (n = 7) were increased serum creatinine (n = 2), severe anemia (n = 1), malaise (n = 1), anorexia (1), depression (n = 1), and no virological response (n = 1). Of the 15 patients who had discontinued treatment, only one with RVR who stopped treatment at week 11 achieved an SVR, but 4 relapse and 10 had no virological response.

Drug-induced skin disorders (rashes, eruptions, and erythema) were found in 33 (51.6%) group A patients and 25 (44.6%) group B patients with no significant difference ($p = 0.449$). Severe skin disorders (grade 3), defined as skin lesions covering >50% of the body surface or rashes with bullae,

ulceration of mucous membrane, epidermal detachment, target lesion or systematic signs, were found in 1 (3.0%) of the 33 subjects in group A and 4 (16%) of the 25 in group B, with no significant difference ($p = 0.081$). These patients who developed skin disorders were able to continue treatment with the prescription by topical corticosteroid or oral administration of glucocorticoids added to antihistamine therapy.

We analyzed the differences in hematological changes between the two groups. The decrease in hemoglobin significantly differed between group A and B patients: the decrease to ≥ 100 g/L, to 85 to <100 g/L, and to <85 g/L, 6 (9.4%), 26 (40.6%), and 32 (50%) of group A patients, respectively, and 23 (41.1%), 14 (25%), and 19 (33.9%) of group B patients, respectively ($p = 0.0006$), as would be expected by the lower level at baseline. No significant differences in white blood cell, neutrophil, or platelet count were observed between the two groups.

Newly occurred and deteriorated comorbidities were found in two group A patients. An asymptomatic man aged 65 years was diagnosed with early gastric cancer at week 12 when a workup was done due to severe anemia. He was treated by endoscopic submucosal dissection of the lesion, completed the triple therapy and achieved an SVR. A symptomatic man aged 62 years was found to have deteriorated diabetes at week 2 and stopped triple therapy. No other comorbidities were found among the other patients.

Discussion

This study shows that there is no impact by age on the virological outcome of TVR-based triple therapy for HCV genotype 1b chronic hepatitis C. Our findings showed significant correlations between virological outcome and early virological response: SVR, RVR, and extremely rapid virological response at day 3 of the treatment for both older and younger patients. Moreover, *IL28B* genotype and prior treatment response are significant independent pretreatment factors for the achievement of SVR by older patients, but prior treatment response does not influence the achievement of SVR by younger patients. To date, no studies have assessed differences in the predictive factors for SVR between older and younger patients who underwent TVR-based triple therapy.

Research Article

Table 3. Demographic and clinical features of chronic hepatitis C genotype 1b patients who received telaprevir, PegIFN- α -2b, and ribavirin triple therapy, classified by age and sustained virological response or non-sustained response.

Characteristics	Group A; patients aged >60 (n = 64)			Group B; patients aged \leq 60 (n = 56)		
	SVR (n = 49)	Non-SVR (n = 15)	<i>p</i> value*	SVR (n = 47)	Non-SVR (n = 9)	<i>p</i> value*
Men, n (%)	17 (34.7)	2 (13.3)	0.113	29 (61.7)	6 (66.7)	0.778
Average age (yr)	66 [7.0]	69 [7.0]	0.094	54 [12]	52 [5.5]	0.814
Body mass index (kg/m ²)	22.6 [3.1]	23.9 [5.2]	0.130	23.5 [3.9]	24.8 [4.0]	0.058
Baseline HCV RNA (log ₁₀ IU/ml)	6.4 [0.6]	6.3 [0.8]	0.691	6.6 [0.9]	6.4 [0.5]	0.433
HCV core amino acid substitution at position 70, wild/mutation, n	29/20	4/11	0.027	21/26	4/5	0.989
White blood cell count ($\times 10^9$ /L)	4210 [1355]	4090 [580]	0.409	5100 [2600]	3700 [2715]	0.224
Hemoglobin level (g/L)	134 [17]	132 [22]	0.261	144 [22]	141 [33]	0.911
Platelet count ($\times 10^9$ /L)	152 [53]	115 [63]	0.002	171 [81]	142 [68]	0.064
Serum albumin (g/L)	39 [5.0]	39 [8.0]	0.430	41 [5.0]	39 [8.0]	0.072
Aspartate aminotransferase (IU/L)	48 [43.5]	70 [70]	0.007	46 [34]	70 [31.5]	0.031
Alanine aminotransferase (IU/L)	53 [65.5]	72 [74]	0.026	53 [68]	64 [41]	0.255
γ -glutamyl-transpeptidase (IU/L)	26 [24]	53 [62]	0.0004	45 [60]	103 [63.2]	0.023
Estimated glomerular filtration rate (ml/min)	75.3 [17.7]	74.4 [15.9]	0.686	83.7 [20.2]	83.1 [20.5]	0.561
Liver histology						
Stage, F0-2/F3-4, n	20/14	1/7	0.018	22/6	2/4	0.027
Stage F0, n	5	0	0.007	2	0	0.067
Stage F1, n	10	0		16	1	
Stage F2, n	5	1		4	1	
Stage F3, n	7	0		4	3	
Stage F4, n	7	7		2	1	
Grade, A0-1/A2-3, n	15/19	0/8	0.019	18/10	1/5	0.033
Not determined, n	15	7		19	3	
Previous treatment outcome						
Treatment naïve, n	12	0	0.084	13	2	0.081
Prior relapse, n	29	6		26	3	
Prior non-response, n	5	9		8	3	
Prior unknown response, n	3	0		0	1	
<i>IL28B</i> SNP (rs8099917)						
TT, n	42	5	<0.0001	34	3	0.023
TG/GG, n	7	10		13	6	
<i>ITPA</i> SNP (rs1127354)						
CC, n	39	12	0.972	35	6	0.628
CA/AA, n	10	3		12	3	
Completed assigned total cumulative PegIFN- α -2b dosage \geq 80% and RBV dosage \geq 80%, n (%)	14 (28.6)	1 (6.7)	0.079	19 (40.4)	5 (55.6)	0.400
Completed assigned total cumulative PegIFN- α -2b dosage \geq 80%, n (%)	44 (89.8)	7 (46.7)	0.0002	40 (85.1)	6 (66.7)	0.185
Completed assigned total cumulative RBV dosage \geq 80%, n (%)	15 (30.6)	1 (6.7)	0.061	20 (42.6)	6 (66.7)	0.184
Discontinuation of PegIFN- α -2b and RBV, n (%)	1 (2.0)	7 (46.7)	<0.0001	1 (2.1)	6 (66.7)	<0.0001
Discontinuation of TVR, n (%)	1 (2.0)	6 (40.0)	<0.0001	1 (2.1)	4 (44.4)	<0.0001
Discontinuation of treatment, n (%)	1 (2.0)	7 (46.7)	<0.0001	0 -	7 (77.8)	<0.0001
RVR, n (%)	42 (85.7)	5 (33.3)	<0.0001	40 (85.1)	1 (11.1)	<0.0001

SVR, sustained virological response; HCV, hepatitis C virus; *IL28B*, interleukin 28B; SNP, single-nucleotide polymorphism; *ITPA*, inosine triphosphate pyrophosphatase; PegIFN- α -2b, pegylated interferon α 2b; RBV, ribavirin; TVR, telaprevir; RVR, rapid virological response.

All patients were infected with HCV genotype 1b.

Continuous variables are expressed as median [interquartile range].

**p* Value draws a comparison between the SVR and non-SVR patients of each group.

We found that the median serum HCV RNA level at day 3 was significantly lower for SVR patients than for non-SVR patients in both older and younger patients. RVR patients have a high potential for achieving an SVR. After a single dose of TVR, the mean half-life is approximately 4 hours. At steady state, the effective half-life is approximately 9–11 hours. When TVR is administered at 750 mg every 8 hours, a steady state is reached from 3 to 7 days after the start of administration

[11–14]. For these reasons, we investigated the correlation between the HCV RNA level at day 3 and virological response. We also showed that lower exposure (accumulated dosage <60%) to TVR within the first 4 weeks of treatment leads to a lower SVR rate; however, other accumulated dosages were not related to SVR. The quick steady state of TVR is presumed to be related to a rapid decline of the HCV RNA level, which leads to RVR and SVR, irrespective of age.

Table 4. Predictive factors associated with sustained virological response by chronic hepatitis C genotype 1b patients who received telaprevir, PegIFN- α -2b and ribavirin triple therapy, classified by age.

	Group A: Patients aged >60 (n = 64)					Group B: Patients aged \leq 60 (n = 56)				
	Simple		Multiple			Simple		Multiple		
	Odds ratio	p value	Odds ratio	95% CI	p value	Odds ratio	p value	Odds ratio	95% CI	p value
Age (per 1 yr)	0.876	0.101				0.975	0.609			
Sex (male to female)	3.448	0.129				0.805	0.778			
Body mass index (per 1 kg/m ²)	0.822	0.062				0.823	0.093			
γ -glutamyl-transpeptidase (per 1 IU/L)	0.971	0.003				0.998	0.709			
White blood cell count (per 1 $\times 10^6$ /L)	1.348	0.093				1.000	0.242			
Hemoglobin level (per 1 g/L)	1.364	0.187				1.043	0.876			
Platelet count (per 1 $\times 10^9$ /L)	1.316	0.004				1.173	0.076			
Histological stage (F3-4 to F0-2)	0.700	0.049				0.136	0.027			
Previous treatment response (treatment naïve and prior relapse to prior non-response)	12.34	0.0004	8.403	1.025-66.67	0.047	2.437	0.259			
<i>IL28B</i> SNP (rs8099917) (TT to TG/GG)	107.5	0.0006	14.93	1.600-142.9	0.017	4.231	0.005	25.34	1.848-1409	0.042
RVR	27.78	0.0003	7.498	1.014-65.42	0.009	45.71	<0.0001	78.35	6.618-4418	0.005

IL28B, interleukin 28B; SNP, single-nucleotide polymorphism; RVR, rapid virological response; PegIFN- α -2b, pegylated interferon α 2b.

The *IL28B* gene-related SNP on chromosome 19 is the most important baseline predictor of SVR in the treatment of chronic hepatitis C patients with PegIFN- α plus RBV [6,17,18]. This study found the *IL28B* genotype to be a significant, independent pre-treatment factor for achievement of SVR in the TVR-based regimen. Several classes of DAA are under development, and it is expected that, when used in combination with PegIFN- α plus RBV, these new drugs will improve SVR and decrease the required duration of treatment [25]. The *IL28B* genotype has an influence on early viral kinetics, even during treatment with interferon-free DAA regimens. Interferon-free regimens produce no difference within 6 days after the start of treatment, but a significant difference in HCV RNA reduction after day 7 between patients with *IL28B* SNP (rs12979860) CC vs. the non-CC genotypes [26]. The host *IL28B* genotype has also been shown to affect the spontaneous clearance of HCV infection [27]. Thus, *IL28B* genotyping will continue to play an important role in determining the likelihood of anti-HCV treatment response.

Older patients have been reported to have a greater frequency of treatment discontinuation or to require a reduction in drug dosage during anti-HCV treatment due to laboratory abnormalities and adverse effects [9,10]. The efficacy and safety of PegIFN- α plus RBV treatment have been documented in a large-scale KULDS research of 1,251 Japanese patients [9]. The findings for HCV genotype 1 have shown that the discontinuation rates due to complications and adverse effects of older patients were almost twice those of younger patients (42.9% vs. 24.4% for the 48-week treatment course, respectively). The present study showed no difference in the SVR and discontinuation rates of older and younger patients. This may be attributed to the fact that the TVR-based regimen is completed in a short period, 24 weeks, and that it results in a higher RVR rate. Moreover, this study did not include the principle of response-guided therapy, but our physicians explained the patients' virological response during the treatment, thus most of the patients knew they were responding and were motivated to continue to receive the treatment.

Surprisingly, our older patient group included a higher female percentage than the younger group, however, no significant differences in virological responses were found. Post-menopause is one of the most predictive factors for failure to achieve an SVR, which links SVR to estrogen secretion [6]. Despite the good

virological response in the older patients to TVR-based treatment, a higher relapse rate was found in the older patients than the younger, but the difference was not significant. Moreover, lower cumulative dosages of PegIFN- α and RBV resulted in lower SVR rates only in the older patients. Our study supports the better drug adherence to improve the chance of SVR for older patients with non-RVR and EOT.

The main adverse effects monitored in this study were rash, serious skin reactions, and anemia. Treatment discontinuation rates for these conditions were compared between older and younger patients. No significant differences in drug-induced skin disorders were found. There was a significant difference in the occurrence of severe anemia between the two groups. As expected, the older patients had higher rates of severe anemia than the younger patients, probably due to significantly lower blood counts at baseline of the older patients than the younger patients. Moreover, one man of the older group developed comorbid early gastric cancer and another had deteriorating diabetes. Care must be taken to protect against the occurrence of such disorders in older patients undergoing triple therapy.

The study has a number of limitations. First, the sample size might provide inadequate statistical power to detect definitive differences between the SVR and non-SVR data of both age groups. However, as far as we know, ours is the first study of a TVR-based regimen to show a significant clinical impact by age. Second, we studied only Japanese patients with HCV genotype 1b. Significant differences in virological response and drug mutations between HCV genotypes 1a and 1b have been reported in DAA-based treatment [28]. Among Japanese, the favorable *IL28B* genotype is found in the majority of the population (about 75%) [6,21,22]. Hence, our results may not be able to be extended to patients with other HCV genotypes or other racial cohorts. Third, our patients received a 24-week triple therapy. TVR has been approved since September 2011 for use in Japan only for the treatment of genotype 1 chronic hepatitis C with a high HCV RNA level (≥ 5.0 log IU/ml). Also, the duration of triple therapy is 24 weeks, with all three agents for the first 12 weeks, then PegIFN- α plus RBV dual therapy for the remaining 12 weeks [14]. However, in Europe, the USA, and Canada, TVR must be administered with PegIFN- α and RBV for all patients for 12 weeks, followed by a response-guided regimen of either 12 or 36

Research Article

additional weeks of PegIFN- α and RBV, depending on early viral response of treatment naïve and prior relapse or prior partial and null response [11–13]. Our results show that patients with RVR can achieve high rates of SVR with 24 weeks of TVR-based triple therapy, irrespective of age. The fact that RVR is such a strong predictor for achieving an SVR may partly be explained by the fact that a 48-week course TVR-triple therapy is not necessary for patients with RVR [29]. Forth, our older patients had no severe baseline comorbidities such as heart, pulmonary, renal, and hematological diseases, namely under favorable baseline conditions, so that the drawn conclusion for the safety by TVR-based triple therapy may be limited. However, our findings that there were no serious newly occurred and deteriorated comorbidities are important. We believe the safety of this therapy is probably due to the shorter period.

In conclusion, in this prospective, multicenter study of HCV genotype 1b chronic hepatitis C patients, we found that older patients achieve a better virological outcome by TVR-based triple therapy than with the traditional dual therapy. *IL28B* genotyping and early virological response indicate the potential to achieve an SVR in these difficult-to-treat older patients.

Financial support

This study was supported in part by a Grant-in-Aid for Comprehensive Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Acknowledgements

We are grateful to Drs. Masayuki Murata, Kyoko Okada, Mosaburo Kainuma, Kazuhiro Toyoda, Hachiro Ohnishi, Kunimitsu Eiraku, Haru Mukae, Motohiro Shimizu, Yuji Harada, Fujiko Mitsumoto, Kohji Takayama, Sakiko Hayasaki, Norihito Satoh, Sho Yamasaki, Azusa Hatashima, Takeshi Ihara, Takeo Hayashi, Hiroaki Ikezaki, Satoshi Hiramine, and Kazuya Ura from the Department of General Internal Medicine, Kyushu University Hospital for assistance in this study. We are also grateful to Mr. Yoshitaka Etoh for his excellent lab work on genotyping the SNPs of *IL28B* and *ITPA*.

References

- [1] Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. *N Engl J Med* 1992;327:1906–1911.
- [2] Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective, multicenter study. *J Hepatol* 2013;58:495–501.
- [3] Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–965.
- [4] Furusyo N, Kajiwara E, Takahashi K, et al. An association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: a project of the Kyushu University Liver Disease Study Group. *J Gastroenterol Hepatol* 2008;23:1094–1104.
- [5] Furusyo N, Murata M, Ogawa E, et al. Ribavirin concentration in the later stages of 48-week pegylated interferon- α 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. *J Antimicrob Chemother* 2011;66:1127–1139.
- [6] Furusyo N, Ogawa E, Sudoh M, et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. *J Hepatol* 2012;57:1186–1192.
- [7] Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). *J Hepatol* 2002;37:500–506.
- [8] Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? *Ann Intern Med* 2004;140:370–381.
- [9] Kainuma M, Furusyo N, Kajiwara E, et al. Kyushu University Liver Disease Study Group pegylated interferon α -2b plus ribavirin for older patients with chronic hepatitis C. *World J Gastroenterol* 2010;16:4400–4409.
- [10] Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. *Liver Int* 2010;30:527–537.
- [11] INCIVEK™ [Package Insert]. Cambridge (MA): Vertex Pharmaceuticals Incorporated; 2011.
- [12] INCIVEK™ [Canada Product Monograph]. Laval, Quebec, Canada: Vertex Pharmaceuticals Incorporated; 2011.
- [13] INCIVO® [EU Summary of Product Characteristics]. Beerse, Belgium: Tibotec BVBA; 2011.
- [14] TELAVIC® [Japan Package Insert]. Osaka, Japan: Mitsubishi Tanabe Pharma; 2011.
- [15] McHutchison JG, Everson GT, Gordon SC, et al. PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009;360:1827–1838.
- [16] Hézode C, Forestier N, Dusheiko G, et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009;360:1839–1850.
- [17] Zeuzem S, Andreone P, Pol S, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011;364:2417–2428.
- [18] Kumada H, Toyota J, Okanou T, et al. Telaprevir with peginterferon and ribavirin for treatment-naïve patients chronically infected with HCV of genotype 1 in Japan. *J Hepatol* 2012;56:78–84.
- [19] Hayashi N, Okanou T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. *J Viral Hepat* 2012;19:e134–e142.
- [20] The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology* 1994;20:15–20.
- [21] Ogawa E, Furusyo N, Murata M, et al. Insulin resistance undermines the advantages of *IL28B* polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. *J Hepatol* 2012;57:534–540.
- [22] Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 2007;46:403–410.
- [23] Ahmed WH, Furusyo N, Zaky S, et al. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia of Egyptian hepatitis C virus patients. *World J Gastroenterol* 2013;19:1387–1395.
- [24] Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. *J Clin Epidemiol* 1994;47:1245–1251.
- [25] Sherman KE, Flamm SL, Afdhal NH, et al. ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med* 2011;365:1014–1124.
- [26] Chu TW, Kulkarni R, Kane EJ, et al. Effect of *IL28B* genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. *Gastroenterology* 2012;142:790–795.
- [27] Thomas DL, Thio CL, Martin MP, et al. Genetic variation in *IL28B* and spontaneous clearance of hepatitis C virus. *Nature* 2009;461:798–801.
- [28] Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. *Gastroenterology* 2007;132:1767–1777.
- [29] Sherman KE, Flamm SL, Afdhal NH, et al. ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med* 2011;365:1014–1024.

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy

Eiichi Ogawa¹, Norihiro Furusyo¹, Makoto Nakamuta², Eiji Kajiwara³, Hideyuki Nomura⁴, Kazufumi Dohmen⁵, Kazuhiro Takahashi⁶, Takeaki Satoh⁷, Koichi Azuma⁸, Akira Kawano⁹, Yuichi Tanabe¹⁰, Kazuhiro Kotoh¹¹, Shinji Shimoda¹², Jun Hayashi^{1,*},
the Kyushu University Liver Disease Study (KULDS) Group

¹Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan; ²Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan; ³Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan; ⁴The Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu, Japan; ⁵Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan; ⁶Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan; ⁷Center for Liver Disease, National Hospital Organization Kokura Medical Center, Kitakyushu, Japan; ⁸Department of Medicine, Kyushu Central Hospital, Fukuoka, Japan; ⁹Department of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan; ¹⁰Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan; ¹¹Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; ¹²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Background & Aims: Anemia is a common adverse effect of telaprevir (TVR) in combination with pegylated interferon (PegIFN) α and ribavirin (RBV) therapy. It occurs at a higher incidence with the TVR relative to PegIFN α and RBV alone. We herein evaluate the baseline and on-treatment predictors of the development of severe anemia by chronic hepatitis C virus (HCV) patients receiving TVR-based triple therapy.

Methods: This prospective, multicenter study consisted of 292 patients (median age: 62 years) infected with HCV genotype 1. All received 12 weeks of TVR in combination with 24 weeks of PegIFN α 2b and RBV. The definition of severe anemia during antiviral treatment is hemoglobin (Hb) <85 g/L.

Results: 101 (34.6%) patients developed severe anemia during the treatment period. Multivariable logistic regression analysis of possible pretreatment predictors of the development of severe anemia extracted baseline Hb <135 g/L (Hazard ratio [HR], 2.53; $p = 0.0013$), estimated glomerular filtration rate <80 ml/min/1.73 m² (HR, 1.83; $p = 0.0265$), and inosine triphosphatase (ITPA) CC genotype (rs1127354) (HR, 2.91; $p = 0.0024$). For patients with ITPA CC ($n = 227$), multivariable logistic regression analysis of possible pretreatment and on-treatment predictors of the devel-

opment of severe anemia extracted Hb level at week 2 (HR, 0.96; $p = 0.0085$) and the initial four weeks of weight-adjusted TVR (HR, 1.05; $p = 0.0281$).

Conclusions: Anemia remains a risk for all patients treated with TVR-based triple therapy. However, ITPA polymorphism (rs1127354) is useful for predicting the development of severe anemia and will be helpful in the management of treatment.

© 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Chronic hepatitis C virus (HCV) infection can result in serious health problems such as decompensated cirrhosis and hepatocellular carcinoma [1–3]. The standard of care regimen that includes pegylated interferon (PegIFN) α and ribavirin (RBV) has been the first line for the past decade, however, the rate of sustained virological response (SVR) that can be achieved using this regimen is only 40–52% for patients infected with HCV genotype 1 [4–6].

Of a number of direct-acting antivirals under investigation, non-structural 3/4A protease inhibitors, including telaprevir (TVR) and boceprevir, have shown promising treatment outcomes in various clinical trials in combination with the current standard of care. The SVR rate is improved to over 70% for HCV genotype 1 patients treated with TVR-based triple therapy [7–9]. Notably, the SVR rate rises to over 80% for prior relapsers [7,10]. However, many adverse effects have been reported, with anemia being one of the most serious. Treatment requires careful management with RBV dose reduction. Because anemia has been shown to occur at a higher incidence with the TVR regimen relative to PegIFN α and RBV alone [7], it is important to understand the characteristics of severe anemia development prior to antiviral treatment.

Keywords: Hepatitis C virus; Anemia; Telaprevir; Inosine triphosphatase; Pegylated interferon; Ribavirin.

Received 5 March 2013; received in revised form 19 April 2013; accepted 13 May 2013; available online 23 May 2013

* Corresponding author. Address: Department of General Internal Medicine, Kyushu University Hospital, Higashi-Ku, Fukuoka 812-8582, Japan. Tel.: +81 92 642 5909; fax: +81 92 642 5916.

E-mail address: hayashij@gim.med.kyushu-u.ac.jp (J. Hayashi).

Abbreviations: HCV, hepatitis C virus; PegIFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological response; TVR, telaprevir; ITPA, inosine triphosphatase; SNP, single nucleotide polymorphism; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; RVR, rapid virological response; HR, hazard ratio; CI, confidence interval; AUROC, area under the receiver operating characteristic curve.



Research Article

A genome-wide association study identified the inosine triphosphatase (*ITPA*) gene single nucleotide polymorphism (SNP) as being significantly associated with RBV-induced anemia [11,12]. Recently, Chayama *et al.* reported in a clinical trial that *ITPA* SNP (rs1127354) is associated with anemia in TVR-based triple therapy and that RBV dose reductions were required significantly earlier for patients with the *ITPA* CC genotype when compared with the *ITPA* CA and AA genotypes [13]. However, further improvement of the ability to predict the development of severe anemia will contribute to increasing the likelihood of achieving an SVR by patients whose treatment might otherwise have to be stopped.

The aim of this multicenter, prospective study was to evaluate the baseline and on-treatment predictors of the development of severe anemia (Hb <85 g/L) by chronic hepatitis C patients treated with TVR-based triple therapy.

Patients and methods

Patients

The Kyushu University Liver Disease Study (KULDS) Group consists of the Kyushu University Hospital and its affiliated hospitals in the northern Kyushu area of Japan. This prospective study consisted of 292 Japanese patients with chronic HCV infection aged 20 years or older who received TVR in combination with Peg-IFN α 2b and RBV between December 2011 and October 2012. Exclusion criteria were: (1) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (2) clinical or biochemical evidence of hepatic decompensation (ascites, bleeding varices, or encephalopathy); (3) baseline hemoglobin (Hb) <120 g/L (female, <60 years), <110 g/L (female, \geq 60 years), <130 g/L (male, <60 years), and <120 g/L (male, \geq 60 years); (4) baseline serum creatinine >1.2 mg/dl (male) and >0.9 mg/dl (female); (5) other causes of liver disease (autoimmune hepatitis, or primary biliary cirrhosis); (6) excessive active alcohol consumption (a daily intake of more than 40 g of ethanol) or drug abuse; (7) suspected hepatocellular carcinoma at entry; or (8) treatment with antiviral or immunosuppressive agents prior to enrollment. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of each participating hospital. Informed consent was obtained from all patients before enrollment.

Clinical and laboratory assessment

Clinical parameters were measured by standard laboratory techniques at a commercial laboratory (SRL Laboratory, Tokyo, Japan). Body mass index was calculated as weight in kilograms/height in square meters. The estimated glomerular filtration rate (eGFR) was calculated based on the Modification of Diet in Renal Disease (MDRD) formula. Aspartate aminotransferase to platelet ratio index (APRI) was calculated, as previously recommended for evaluating severe liver fibrosis [14].

Assessment of liver fibrosis

Liver biopsy for 183 (62.7%) of the studied patients was done by experienced hepatologists. All antiviral treatment was initiated within one month after liver biopsy. The minimum length of the liver biopsy was 15 mm and at least 10 complete portal tracts were necessary for inclusion. For each specimen, the stage of fibrosis was established according to the METAVIR score [15].

Antiviral treatment

All patients received a combination treatment of TVR (Telaviv; Mitsubishi Tanabe Pharma, Osaka, Japan), PegIFN α 2b (PEG-Intron; MSD, Tokyo, Japan), and RBV (Rebetol; MSD) for 12 weeks, followed by an additional 12 weeks of PegIFN α 2b and RBV alone. TVR 750 mg was administered three times a day at an 8-h interval after each meal (2250 mg/day). PegIFN α 2b was injected subcutaneously once weekly at a dose of 1.5 μ g/kg. RBV was given orally at a daily dose of 600–1000 mg based on body weight (600 mg for patients weighing <60 kg, 800 mg for those weighing 60–80 kg, and 1000 mg for those weighing >80 kg). The above

durations and dosages are those approved by the Japanese Ministry of Health, Labor, and Welfare. In case of a 1.5 to 2.0 times elevation from baseline serum creatinine, the TVR dose was reduced to 1500 mg/day (750 mg twice a day at a 12-h interval after each meal). When serum creatinine was elevated to over 2.0 times the baseline level, TVR was discontinued. If a marked anorexia was developed, the TVR dose could be reduced to 1500 mg/day. If a progressive grade 3 rash developed (severe, involving more than 50% of the body surface, or rash with the appearance of substantial systemic signs of symptoms), TVR was discontinued. However, the patients continued to receive PegIFN and RBV in all of these situations. All treatment was discontinued for patients with less than 2 log₁₀ HCV RNA decrease from baseline to week 12.

Management of anemia

Severe anemia during antiviral treatment was defined as Hb <85 g/L. Complete blood count was checked every week for the first 12 weeks and then at weeks 16, 20, and 24. The management of anemia started with RBV dose reduction. Specifically, the RBV dose was reduced by 200 mg for patients receiving 600 or 800 mg and by 400 mg for those receiving 1000 mg when Hb decreased to <120 g/L and by an extra 200 mg when it lowered to <100 g/L. If Hb decreased to <90 g/L, the TVR dose was reduced to 1500 mg/day. Erythropoietin use was not allowed during treatment, but blood transfusion was allowed when necessary. Discontinuation of TVR-based triple therapy due to severe anemia was primarily based on the discretion of the physicians at each hospital.

HCV RNA level and HCV genotype

Clinical follow-up of HCV viremia was done by real-time reverse transcriptase PCR assay (COBAS[®] TaqMan[®] HCV assay) (Roche Diagnostics, Tokyo, Japan), with a lower limit of quantitation of 15 IU/ml and an upper limit of quantitation of 6.9×10^7 IU/ml (1.2 to 7.8 log IU/ml referred to log₁₀ IU/ml) [16]. HCV RNA levels were measured at baseline, regularly during treatment, at early discontinuation, and at follow-up visits after the end of treatment. Virological response was categorized as follows: rapid virological response (RVR) was an undetectable HCV RNA at week 4 and SVR was an undetectable HCV RNA at week 24 after the end of treatment. HCV genotype determination was by sequence determination in the 5'-non-structural region of the HCV genome followed by phylogenetic analysis [17].

Genetic testing

Human genomic DNA was extracted from peripheral blood. Genotyping of the *ITPA* (rs1127354) genes was performed using the ABI TaqMan allelic discrimination kit (7500 Real Time PCR System; Applied Biosystems, Carlsbad, CA, USA). Heterozygotes (CA) or homozygotes (AA) of the minor allele (A) are described as having the *ITPA* minor allele, whereas homozygotes for the major allele (CC) are described as having the *ITPA* major allele [12].

Statistical analysis

Statistical analyses were conducted using SPSS statistics 19.0 (IBM SPSS Inc, Chicago, IL, USA). Baseline continuous data are expressed as median (first-third quartiles) or mean (\pm standard deviation), and categorical variables are reported as frequencies and percentages. Univariate analyses were done using the Chi-square, Fisher's exact, or Mann-Whitney U tests as appropriate. Variables with $p < 0.05$ in univariate analysis were evaluated using multivariate logistic regression to identify variables significantly associated with the development of severe anemia. The results are expressed as hazard ratios (HR) and their 95% confidence interval (CI). The significance of trends in values was determined with the Cochran-Armitage trend test.

Area under the receiver operating characteristic curve (AUROC) analysis was done to evaluate the relationship between the Hb level and development of severe anemia. The cut-off values were selected from the receiver operating characteristic (ROC) curve to maximize the total sensitivity and specificity. A p value less than 0.05 was regarded as statistically significant in all analyses.

Results

Patient characteristics and the development of severe anemia

The baseline characteristics of the 292 studied patients as classified by the development of severe anemia are shown in Table 1.

Table 1. Baseline risk factors for the development of severe anemia by chronic hepatitis C patients treated with telaprevir-based triple therapy.

Characteristic	All patients n = 292	Severe anemia n = 101	Non-severe anemia n = 191	p value*
Age (yr)	62 (54-66)	64 (57-68)	60 (53-65)	<0.0001
Men, n (%)	135 (46.2)	33 (32.7)	102 (53.4)	0.0007
Body mass index (kg/m ²)	23.3 (21.6-25.6)	22.9 (20.9-25.1)	23.4 (21.8-25.7)	0.0408
Alanine aminotransferase (IU/L)	50 (33-93)	50 (30-93)	50 (34-93)	0.3499
Serum albumin (g/L)	40 (37-42)	39 (36-42)	40 (38-43)	0.0054
Estimated glomerular filtration rate (ml/min/1.73 m ²)	80 (72-92)	76 (70-90)	83 (74-94)	0.0024
α -fetoprotein (ng/ml)	5.4 (3.5-11.0)	5.4 (3.3-10.2)	5.5 (3.6-11.7)	0.1753
Hemoglobin (g/L)	136 (127-147)	132 (124-140)	141 (133-153)	<0.0001
Platelet count (x10 ⁹ /L)	154 (120-190)	150 (118-200)	156 (121-189)	0.9279
HCV RNA level (log ₁₀ IU/ml)	6.5 (6.0-6.9)	6.4 (6.1-6.8)	6.5 (6.0-6.9)	0.5359
APRI <2.0/≥2.0, n (%)	234/58 (80.1/19.9)	77/24 (32.9/41.4)	157/34 (67.1/58.6)	0.2292
Stage of fibrosis				
F0-2/F3-4, n (%)	117/66 (63.9/36.1)	43/28 (36.8/42.4)	74/38 (63.2/57.6)	0.4505
Not determined, n (%)	109	30	79	
<i>ITPA</i> SNPs (rs1127354) CC/CA or AA, n (%)	227/65 (77.7/22.3)	90/11 (39.6/16.9)	137/54 (60.4/83.1)	0.0004
Treatment-naïve/experienced, n (%)	90/202 (30.8/69.2)	32/69 (35.6/34.2)	58/133 (64.4/65.8)	0.8169

Data are expressed as number (%) or median (first-third quartiles).

All demographic and clinical data are those at the start of antiviral treatment.

Severe anemia is diagnosed by hemoglobin level <85 g/L during antiviral treatment.

HCV, hepatitis C virus; *ITPA*, inosine triphosphatase; SNP, single nucleotide polymorphism; APRI, aspartate aminotransferase to platelet ratio index.

*Comparison between severe anemia and non-severe anemia.

HCV genotype 1b was detected in 290 (99.3%) patients and genotype 1a in the other two. Severe anemia (Hb <85 g/L) was developed during the treatment period by 101 of the 292 (34.6%) patients. The percentages of patients experiencing on-treatment severe anemia are shown in Fig. 1. No patient experienced severe anemia before week 2, and only two patients developed severe anemia after week 12. The onset of severe anemia was most frequently seen from weeks 8 to 12. The allele of the *ITPA* SNP (rs1127354) was determined for each patient. The percentages of patients with the *ITPA* CC, CA, and AA genotypes were 77.7% (n = 227), 19.2% (n = 56), and 3.1% (n = 9), respectively. There were no significant differences in sex (male 45.4% and 49.2%), age (median 62 and 59 years), BMI (23.2 and 23.7 kg/m²), eGFR (80 and 83 ml/min/1.73 m²), baseline Hb level (137 and 139 g/L), or initial four-week RBV dosage (9.7 and 10.5 mg/kg) between the *ITPA* CC and CA/AA genotypes.

Baseline factors associated with the development of severe anemia

Univariate analysis extracted older age ($p < 0.0001$), female sex ($p = 0.0007$), lower BMI ($p = 0.0408$), lower serum albumin ($p = 0.0054$), lower eGFR ($p = 0.0024$), lower baseline Hb level ($p < 0.0001$), and *ITPA* CC ($p = 0.0004$) as significantly associated with the development of severe anemia during treatment (Table 1). Prior therapeutic experience was not associated with the development of severe anemia ($p = 0.8169$). In multivariable logistic regression analysis of possible pretreatment predictors of the development of severe anemia, significant independent pretreatment predictors were baseline Hb <135 g/L (HR, 2.53; 95% CI, 1.43–4.51; $p = 0.0013$), eGFR <80 ml/min/1.73 m² (HR, 1.83; 95% CI, 1.07–3.16; $p = 0.0265$), and *ITPA* CC (HR, 2.91; 95% CI, 1.44–6.32; $p = 0.0024$). No independent predictive relationship was found between age, sex, BMI, or serum albumin. The rates of severe anemia development stratified by

ITPA genotype (CC and CA/AA), eGFR level (≥ 80 and <80 ml/min/1.73 m²), and baseline Hb level (≥ 135 and <135 g/L) are shown in Fig. 2.

Hb levels during antiviral treatment stratified by *ITPA* SNPs are shown in Fig. 3A. Hb levels from week 2 to week 24, except at week 12, for patients with *ITPA* CC were significantly lower than those of patients with *ITPA* CA/AA. Similarly, Hb decrement and the decrease ratio throughout the initial 12 weeks stratified by *ITPA* SNPs are shown in Fig. 3B and C, respectively. Hb decrement and the decrease ratio from week 2 to week 8 for patients with *ITPA* CC were significantly lower than for patients with *ITPA* CA or AA.

Baseline factors associated with Hb decrease by over 50 g/L

Hb decline over 50 g/L during the treatment period was found for 128 of the 292 (43.8%) patients. Univariate analysis extracted younger age ($p = 0.0011$), male sex ($p = 0.0011$), lower eGFR ($p = 0.0161$), higher baseline Hb level ($p < 0.0001$), and *ITPA* CC ($p = 0.0009$) as significantly associated with the decline of Hb to ≥ 50 g/L. In multivariable logistic regression analysis, baseline Hb ≥ 135 g/L (HR, 2.73; 95% CI, 1.55–4.86; $p = 0.0005$), eGFR <80 ml/min/1.73 m² (HR, 1.74; 95% CI, 1.04–2.93; $p = 0.0355$), and *ITPA* CC (HR, 3.36; 95% CI, 1.78–6.63; $p = 0.0001$) were independently associated with an Hb decline of over 50 g/L.

Relationship between pretreatment or on-treatment variables and the development of severe anemia stratified by *ITPA* SNPs

Table 2 shows the development of severe anemia according to the *ITPA* SNPs. Univariate analysis of patients with *ITPA* CC (n = 227) extracted older age ($p = 0.0004$), female sex ($p = 0.0011$), lower serum albumin ($p = 0.0083$), lower eGFR ($p = 0.0041$), lower baseline Hb level ($p < 0.0001$), lower Hb level

Research Article




Fig. 1. The percentage of patients experiencing on-treatment severe anemia (hemoglobin <85 g/L). No patient experienced severe anemia before week 2, and the onset of severe anemia was most frequently observed from weeks 8 to 12.




Fig. 2. The percentages of patients who developed severe anemia stratified by ITPA SNPs (rs1127354), baseline estimated glomerular filtration rate (eGFR), and hemoglobin (Hb) level. The percentages of ITPA CC patients with severe anemia were significantly increased with lower eGFR and Hb levels. Severe anemia was developed by only 16.9% of the ITPA CA/AA patients (the Cochran-Armitage trend test: $p < 0.0001$).

at week 2 ($p < 0.0001$), and higher initial four week weight-adjusted dosage of TVR ($p = 0.0455$) as significantly associated with the development of severe anemia. In multivariable logistic regression analysis of possible pretreatment and on-treatment predictors of the development of severe anemia, significant independent predictors were Hb level at week 2 (HR, 0.96; 95% CI, 0.93–0.98; $p = 0.0085$) and the initial four weeks of weight-adjusted TVR (HR, 1.05; 95% CI, 1.01–1.10; $p = 0.0281$). The percentages of ITPA CC patients experiencing on-treatment severe anemia stratified by the initial four weeks of TVR (25 mg/kg/day) are shown in Fig. 4A. The rates of severe anemia of the TVR ≥ 25 mg/kg/day group were significantly higher than those of the TVR <25 mg/kg/day group at weeks 7, 8, 12, 16, and 24.

In contrast, univariate analysis of patients with ITPA CA/AA ($n = 65$) extracted only lower baseline Hb level ($p = 0.0022$) and lower Hb level at week 2 ($p = 0.0081$) as significantly associated

with the development of severe anemia. No predictive relationship was found between age, sex, eGFR, or the initial weight-adjusted dosages of RBV or TVR and the development of severe anemia. The percentages of ITPA CA/AA patients experiencing on-treatment severe anemia are shown in Fig. 4B. Severe anemia was developed only between weeks 7 and 16, unlike patients with ITPA CC.

ROC curve analysis of the Hb level at week 2 and the development of severe anemia by patients with ITPA CC

The adequacy of the multivariate model was confirmed by a ROC curve analysis. This analysis was performed to determine the optimal threshold values for the Hb level at week 2 for predicting the development of severe anemia by the 227 patients with ITPA CC. The corresponding AUROC was 0.70 ($p < 0.0001$) for ITPA CC and the cut-off value for the Hb level at week 2 was 116 g/L (sensitivity 79.0%, specificity 57.0%).

ROC curve analyses of the Hb level at baseline and week 2 and the development of severe anemia by patients with ITPA CA/AA

ROC curve analyses were performed to determine the optimal threshold values for the Hb levels at baseline and week 2 for predicting the development of severe anemia by the 65 patients with ITPA CA/AA. The corresponding AUROCs were 0.75 ($p = 0.0089$) for Hb level at baseline (cut-off values 122 g/L; sensitivity 98.0%, specificity 55.0%) and 0.68 ($p = 0.0538$) for Hb level at week 2, which indicates that the Hb level at baseline is more effective than that at week 2 for predicting the development of severe anemia by patients with ITPA CA/AA.

Treatment efficacy

The overall rates of RVR and SVR were 75.0% (219 of 292) and 82.2% (240 of 292), respectively. The RVR and SVR rates of patients with ITPA CC were 74.9% (170 of 227) and 81.5% (185 of 227), respectively. For patients with ITPA CC, there was no significant difference in the initial four weeks of weight-adjusted TVR between the RVR (28.7 [24.4–33.1] mg/kg/day) and non-RVR groups (28.7 [23.9–31.7] mg/kg/day) ($p = 0.2467$). However, the SVR rates for the initial four weeks of the TVR ≥ 25 group (83.5%, 137 of 164) were higher than those of the TVR <25 (mg/kg/day) group (76.2%, 48 of 63), but did not reach significance ($p = 0.2106$).

Premature discontinuation of treatment or blood transfusion due to anemia

Of the 292 patients, 38 (13.0%) had TVR-based triple therapy discontinued during the treatment period. Of these 38 patients, 8 (21.1%) had treatment discontinued because of severe anemia between weeks 8 and 16. Of these 8 patients, 5 (62.5%) were women, 6 (66.7%) were aged over 60 years, and 6 (66.7%) were ITPA CC. On the other hand, 23 (7.9%) received blood transfusion without treatment discontinuation. Of these 23 patients, 13 (56.5%) were women, 16 (69.6%) were aged over 60 years, and 18 (78.3%) were ITPA CC.

Discussion

This prospective, multicenter study was carried out to evaluate the baseline and on-treatment predictors of the development of




Fig. 3. Mean hemoglobin (Hb) levels, Hb decrement, and Hb decrease ratio during antiviral treatment stratified by *ITPA* SNPs. (A) Hb levels from week 2 to week 24, except at week 12, for patients with *ITPA* CC were significantly lower than those of patients with *ITPA* CA/AA. (B) Hb decrement from week 2 to week 8 for patients with *ITPA* CC was significantly lower than for those with *ITPA* CA/AA. (C) The Hb decrease ratio from week 2 to week 8 for patients with *ITPA* CC was also significantly lower than for those with *ITPA* CA/AA.

severe anemia (Hb <85 g/L) by patients treated with TVR in combination with PegIFN α 2b and RBV. Several pretreatment factors, including lower baseline Hb level, lower eGFR, and *ITPA* CC (rs1127354) genotype, were independently associated with the development of severe anemia. Moreover, analysis of patients with the *ITPA* CC genotype that included baseline and on-treatment parameters found the Hb level at week 2 and the initial four week, weight adjusted dosage of TVR to be independent, significant predictors of the development of severe anemia. These findings will help increase the rate of successful completion of treatment by allowing doctors to take steps to predict severe anemia according to the *ITPA* polymorphism.

The availability of protease inhibitors has profoundly changed the management of chronic hepatitis C by achieving higher rates of SVR. However, adverse events are experienced by almost all patients. The most frequently reported adverse effects associated with TVR have been hematological disorders (anemia, thrombocytopenia and leukocytopenia), skin disorders (pruritus and rash), gastrointestinal disorders (nausea and diarrhea), general fatigue, and elevated serum levels of uric acid, bilirubin, and creatinine [7–9,18,19]. Moderate and severe anemia has been shown to develop more frequently in TVR-based triple therapy than in PegIFN α 2b and RBV alone [7] and by Japanese more often than by Americans/Europeans [18,19] because Japanese patients with

chronic hepatitis C average more than 10 years older than those in Western countries [20–22]. However, these findings were based on clinical trials, thus this is the first study to show the predictors of development of severe anemia as evaluated in clinical practice.

Severe anemia leads to hypoxia in organs, and this condition may be a sign of hyperdynamic circulation, tachycardia, and left heart strain, which have the potential risk of heart failure. Our results showed that the development of severe anemia began at week 3, with a peak frequency at week 12. Therefore, it is important to adjust the dosage as needed in order for patients to be able to complete the overall treatment duration.

We investigated the baseline characteristics associated with both the development of severe anemia and Hb decline by over 50 g/L. *ITPA* CC genotype and lower eGFR level were extracted as the independent risk factors in common. In the analysis of Hb decline, a higher baseline Hb level was extracted as an independent factor of higher Hb decline during treatment. This finding can be interpreted in relation to the more adequate RBV adherence of the patients with high baseline Hb levels. The above show the importance of TVR-based triple therapy strategy adjustment according to the *ITPA* SNPs (rs1127354). Of the patients with *ITPA* CC, 39.6% developed severe anemia during treatment. Their Hb levels after week 2 were significantly lower than those

Research Article

Table 2. Baseline and initial on-treatment risk factors for the development of severe anemia according to the *ITPA* SNPs (rs1127354) of chronic hepatitis C patients treated with telaprevir-based triple therapy.

Characteristic	<i>ITPA</i> CC, n = 227			<i>ITPA</i> CA/AA, n = 65		
	Severe anemia, n = 90	Non-severe anemia, n = 137	<i>p</i> value	Severe anemia, n = 11	Non-severe anemia, n = 54	<i>p</i> value
Age (yr)	64 (57-68)	61 (53-65)	0.0004	63 (55-68)	58 (53-65)	0.0900
Men, n (%)	29 (32.2)	74 (54.0)	0.0011	4 (36.4)	28 (51.9)	0.3462
Body mass index (kg/m ²)	22.8 (20.9-25.0)	23.4 (21.8-25.6)	0.0939	23.1 (20.3-25.4)	23.7 (21.8-26.9)	0.4305
Alanine aminotransferase (IU/L)	49 (29-95)	53 (34-94)	0.1157	56 (36-79)	45 (33-97)	0.3216
Serum albumin (g/L)	39 (36-42)	40 (38-43)	0.0083	39 (34-43)	39 (38-43)	0.1973
Estimated glomerular filtration rate (ml/min/1.73 m ²)	76 (69-91)	82 (74-95)	0.0041	74 (67-89)	84 (74-93)	0.2634
α -fetoprotein (ng/ml)	5.4 (3.3-11.0)	5.7 (3.5-12.5)	0.3010	5.6 (3.9-9.9)	5.2 (4.1-10.7)	0.2180
Hemoglobin at baseline (g/L)	132 (125-140)	141 (132-153)	<0.0001	121 (117-140)	141 (133-149)	0.0022
Hemoglobin at week 2 (g/L)	114 (110-123)	125 (117-136)	<0.0001	124 (110-143)	138 (131-144)	0.0081
Platelet count (x10 ⁹ /L)	144 (113-197)	153 (117-190)	0.9107	166 (147-222)	159 (131-187)	0.2659
Stage of fibrosis						
F0-2/F3-4, n (%)	37/25 (39.4/50.0)	57/25 (60.6/50.0)	0.2205	6/3 (26.1/18.8)	17/13 (73.9/81.3)	0.5895
Not determined	28	55		2	24	
Initial 4 week ribavirin dose (mg/kg/day)	10.0 (7.6-11.0)	9.4 (7.8-10.8)	0.8369	9.8 (7.0-11.4)	10.5 (8.6-11.4)	0.7143
Initial 4 week telaprevir dose (mg/kg/day)	29.9 (25.8-33.2)	28.0 (23.9-31.3)	0.0455	27.1 (23.4-31.2)	28.7 (22.6-33.2)	0.8818

Data are expressed as number (%) or median (first-third quartiles).
ITPA, inosine triphosphatase; SNP, single nucleotide polymorphism.
 Severe anemia is defined as hemoglobin level <85 g/L.

of patients with *ITPA* CA/AA. Multivariable logistic regression analysis of pretreatment and early on-treatment predictors of development of severe anemia found lower Hb level at week 2 to be an independent factor. Thus, the degree of Hb decline in the first two weeks profoundly influenced the development of severe anemia because the Hb level reduced continuously until week 12. ROC analysis showed that the AUROC was 0.70 ($p < 0.0001$), confirming that the Hb level at week 2 (cut-off value: 116 g/L) is a moderately effective predictive marker of severe anemia. Moreover, we showed that severe anemia is associated with the initial four-week weight-adjusted dosage of TVR but not RBV. Considering that the initial dosage of TVR had a small impact on treatment outcome as we have shown, reduction may be needed in clinical practice to prevent the development of severe anemia. Obviously, further studies are needed to clarify the association between treatment outcome and TVR adherence.

In contrast, 16.9% of the patients with *ITPA* CA/AA developed severe anemia during treatment. At week 12, the Hb level and Hb decline from baseline of patients with *ITPA* CA/AA were almost equal to those of patients with *ITPA* CC. The reason is thought to be RBV adherence; there was a significant difference between *ITPA* CC (7.4 ± 2.2 mg/kg/day) and CA/AA groups (9.1 ± 2.4 mg/kg/day) ($p < 0.0001$) in the initial 12-week dosage of RBV, but no difference in TVR. Although no close relationship was found between age, sex, BMI, or treatment adherence and the odds of subsequent severe anemia onset, only a lower Hb level was found to influence severe anemia. Moreover, ROC analysis showed an AUROC of 0.75, confirming that the baseline Hb level (cut-off value: 122 g/L) is a moderately effective predictive marker of severe anemia for patients with *ITPA* CA/AA. According to these findings, a treatment strategy tailored to the patient *ITPA* polymorphism would help individualize the clinical management of TVR-based triple therapy.

Several *ITPA* gene mutations have been described that are related to *ITPA* deficiency [23,24], which leads to an accumulation of inosine triphosphatase in red blood cells and increased toxicity of purine analogue drugs [25,26], although the exact mechanisms through which TVR in combination with PegIFN α 2b and RBV causes severe anemia remains obscure. Two functionally deficient variants (rs1127354 and rs7270101) of *ITPA* were recently found to protect against anemia. However, the splicing variant SNP rs7270101 is monoallelic in the Japanese population [12], thus, only the *ITPA* variant rs1127354 was tested in this study.

A limitation of this study is that it consists of only Japanese participants. As is characteristic of Japanese chronic hepatitis C patients, almost all are infected with HCV genotype 1b (patients infected with genotype 1a are very rare), the rates of obesity and patients under 60 years are much lower than those found in other ethnic groups, and the overwhelming majority of our patients had the *ITPA* CC genotype. Further studies of other ethnic groups and patients with the *ITPA* CA and AA genotypes are needed to clarify the findings. Nevertheless, we provided significant information because the study included patients of older age who are considered to be at high risk of development of anemia. Second, the patients received only 24 weeks of total therapy (TVR-based triple therapy of 12 weeks followed by only 12 weeks of dual-therapy), which is not the same as the response-guided therapy that is standard elsewhere, but it is the approved regimen of the Japanese Ministry of Health, Labor, and Welfare. However, almost all patients who developed severe anemia (98.0%, 99 of 101) first experienced it during the initial 12 weeks of treatment. Therefore, the frequency of severe anemia was little affected by the treatment duration. Third, Japanese patients received lower dose RBV than is standard elsewhere, and TVR dose reduction due to adverse effects has not been reported previously. In fact, currently there is insufficient evidence to allow